At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 114 enrolled
Drug / intervention
Oxymetazoline hydrochloride 0.1% ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Palpebral Fissure Height, Eye Redness, and Patient-reported Eye Appearance
In Brief
A Phase 4 clinical trial evaluating Oxymetazoline hydrochloride 0.1% ophthalmic solution and Placebo for Ptosis, Eyelid and 2 related conditions. Completed, enrolled 114 participants across 1 site.
Detailed Summary
The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPtosis, Eyelid, Conjunctiva Inflamed, Eye Manifestations
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJun 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedApr 5, 2021
Enrollment StartJun 8, 2021
Primary CompletionApr 1, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.2 years ago
Interventions
Oxymetazoline hydrochloride 0.1% ophthalmic solutiondrug
One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.
Placebodrug
One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.